PRODUCT INFORMATION



Taurohyodeoxycholic Acid (sodium salt)

Item No. 21956

CAS Registry No.:	38411-85-7		
Formal Name:	2-[[(3α,5β,6α)-3,6-dihydroxy-	\sim	0
	24-oxocholan-24-yl]amino]-	- ```	4
	ethanesulfonic acid, monosodium salt	:н	
Synonyms:	Taurine Hyodeoxycholate, THDCA		/s
MF:	$C_{26}H_{44}NO_6S \bullet Na$		Н `О-
FW:	521.7	Γ Τ΄ Η΄ Τ΄ Η΄	
Purity:	≥95%		• Na+
Supplied as:	A crystalline solid		
Storage:	-20°C	OH	
Stability:	≥2 years		
Information represents	s the product specifications. Batch specific and	alvtical results are provided on each cer	tificate of analysis.

Laboratory Procedures

Taurohyodeoxycholic acid (THDCA) (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the THDCA (sodium salt) in the solvent of choice, which should be purged with an inert gas. THDCA (sodium salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of THDCA (sodium salt) in ethanol and DMSO is approximately 20 mg/ml and approximately 30 mg/ml in DMF.

THDCA (sodium salt) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, THDCA (sodium salt) should first be dissolved in DMF and then diluted with the aqueous buffer of choice. THDCA (sodium salt) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

THDCA is a taurine-conjugated form of the secondary bile acid hyodeoxycholic acid (Item No. 20294).¹ THDCA decreases the size and weight of human gallstones in vitro. It increases bile flow, biliary cholesterol secretion, and biliary lipid secretion in rats.² Co-administration of THDCA with taurochenodeoxycholic acid (TCDCA; Item No. 20275) prevents TCDCA-induced hepatotoxicity, increasing bile flow as well as biliary acid and phospholipid secretion in rats.³ THDCA also reduces myeloperoxidase activity, expression of TNF- α and IL-6, and colonic damage in a mouse model of TNBS-induced ulcerative colitis.⁴

References

- 1. Angelico, M., Mogavero, L., Baiocchi, L., et al. Dissolution of human cholesterol gallstones in bile salt/lecithin mixtures: Effect of bile salt hydrophobicity and various pHs. Scand. J. Gastroenterol. 30(12), 1178-1185 (1995).
- 2. Angelico, M., Baiocchi, L., Nistri, A., et al. Effect of taurohyodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid secretion in the rat. Dig. Dis. Sci. 39(11), 2389-2397 (1994).
- 3. Roda, A., Piazza, F., Baraldini, M., et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology 27(2), 520-525 (1998).
- 4. He, J., Liang, J., Zhu, S., et al. Protective effect of taurohyodeoxycholic acid from Pulvis Fellis Suis on trinitrobenzene sulfonic acid induced ulcerative colitis in mice. Eur. J. Pharmacol. 670(1), 229-235 (2011).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/06/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM